Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2007
03/14/2007CN1930126A 吡啶酮衍生物 Pyridine derivatives
03/14/2007CN1929867A Gene therapy for tumor using minus-strand rna viral vectors encoding immunostimulatory cytokines
03/14/2007CN1929864A Complex particles and coated complex particles
03/14/2007CN1929863A Antineoplastic combinations of CCI-779 and rituximab
03/14/2007CN1929862A Use of antagonist anti-CD40 antibodies for treatment of chronic lymphocytic leukemia
03/14/2007CN1929842A Use of camptothecin derivatives for the treatment of proliferative diseases in a fixed dosing regimen
03/14/2007CN1929824A Soft gelatin capsule comprising omega-3-polyunsaturated fatty acid
03/14/2007CN1927883A 新的细胞因子zalpha11配体 New cytokine zalpha11 Ligand
03/14/2007CN1927881A Polypeptide, preparation method thereof, pharmaceutical composition and vaccine containing the same and application thereof
03/14/2007CN1927879A Thymopentapeptide active isomer and application thereof in pharmaceutical preparation
03/14/2007CN1927877A siRNA for inhibiting human Ezrin gene expression and expression carrier thereof
03/14/2007CN1927870A Novel ligand platinum compounds
03/14/2007CN1927862A Garcinia acid derivatives, preparation method and application thereof in pharmacy
03/14/2007CN1927861A Garcinia acid derivatives, preparation method and application thereof in pharmacy
03/14/2007CN1927841A Carbonyl additive derivative of geldanamycin benzoquinone, preparation method and use thereof
03/14/2007CN1927840A Aromatic reductive derivative of geldanamycin benzoquinone, preparation method and use thereof
03/14/2007CN1927839A Compound of 1,4-di(arylamido substituted alkylamino)-5,8-dihydroxyanthraquinone and preparation method thereof
03/14/2007CN1927405A Combination immunizing preparation comprising recombinant plasmid and duplicate deficit type recombinant adenovirus
03/14/2007CN1927404A Application of siRNA inhibiting human Ezrin gene expression in esophagus cancer cell traveling invasion research
03/14/2007CN1927402A Construction and preparation of tumor target gene transmission non-viral vector
03/14/2007CN1927401A Self-assembly composite nano granule tumor vaccine and method for preparing same
03/14/2007CN1927400A Biomagnetism nano target anti-cancer drug and its preparation
03/14/2007CN1927399A Application of non-nucleoside virus reverse transcriptase inhibiting compound and derivative thereof for anti-hepatitis B virus purpose
03/14/2007CN1927398A Medicinal composition comprising active components of 5-HT 3 receptor antagonist and H2 receptor antagonist and use thereof
03/14/2007CN1927387A Application of interleukins-15 in preparation of medicine for tumor immunization therapy and immunotherapy drug
03/14/2007CN1927367A Aromatic turmeric oil nano emulsion and its preparation process
03/14/2007CN1927336A Medicine for treating cancer
03/14/2007CN1927318A Traditional Chinese medicine composition for treating cancer
03/14/2007CN1927307A Chinese herbal medicine prescription for treating cancer
03/14/2007CN1927237A Use of Chinese sealavender for preparing antineoplastic drug
03/14/2007CN1927221A Medicine for killing cancer cell and inhibiting malignant tumor transition
03/14/2007CN1927203A Nano micelle preparation of Catharanthus roseus alkaloids antineoplastic drugs with coating of phospholipid derived from polyethylene glycol
03/14/2007CN1927190A Letrozole transdermal drug administration plaster and its preparation method
03/14/2007CN1927183A Antineoplasma medicine pidorubicin slow release microsphere preparation and method for preparing same
03/14/2007CN1927180A Anticancer slow release injection comprising tetrazole violet and potentiating agent thereof
03/14/2007CN1927179A Compound recipe anticancer slow release injection comprising tetrazole violet
03/14/2007CN1927178A Slow release injection loading both tetrazole violet and cytotoxic drug
03/14/2007CN1927177A Anticancer drug composition loading both platinum compound and tetrazole violet
03/14/2007CN1927176A Anticancer slow release comprising tetrazole violet and cytotoxic drug
03/14/2007CN1927175A Compound recipe anticancer slow release injection comprising tetrazole violet
03/14/2007CN1927174A Anticancer slow release injection loading tetrazole violet and potentiating agent thereof
03/14/2007CN1927173A Compound recipe anticancer slow release agent comprising tetrazole violet
03/14/2007CN1927172A Anticancer slow release agent comprising tetrazole violet and potentiating agent thereof
03/14/2007CN1927171A Anticancer slow release comprising tetrazole violet and cytotoxic drug
03/14/2007CN1927170A Anticancer slow release agent loading both newborn blood vessel and tetrazole violet
03/14/2007CN1927169A Norcantharidin magnetic nano microsphere and its preparing process
03/14/2007CN1304573C NDRG2 and NDRG4 protein and their use for diagnosing and suppressing tumour
03/14/2007CN1304572C Modified antisense nucleotides complementary to section of human Ha-Ras gene
03/14/2007CN1304567C Method and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
03/14/2007CN1304559C Oncolytic microorganism expressing heat shock protein and its application
03/14/2007CN1304427C Angiogenesis inhibiting fusion protein and its use
03/14/2007CN1304418C Nuclear factor-K B P65 subunit antagonistic peptide and its use
03/14/2007CN1304410C Tumor necrosis factor-Gamma
03/14/2007CN1304408C Derivative of vibothymidine and its preparation process and application
03/14/2007CN1304396C Derivative of canthardin and preparation method
03/14/2007CN1304395C New camptothecin analogue compounds, a process for their preparation and pharmaceutical compositions containing them
03/14/2007CN1304382C New p2X* receptor antagonists for use in the treatment of inflammatory immune or cardiovascular diseases
03/14/2007CN1304380C Benzo[alpha]phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II
03/14/2007CN1304377C Metalloproteinase inhibitors
03/14/2007CN1304375C Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
03/14/2007CN1304370C Acenaphthene heterocyclic compound and its cell fading inducing and anti-tumor use
03/14/2007CN1304058C Water soluble paclitaxel prodrugs
03/14/2007CN1304054C Combination of slow released anticancer medication
03/14/2007CN1304053C Composition medicine for curing acute early-young granulocytic leukemia
03/14/2007CN1304051C PSGL-1 regulator
03/14/2007CN1304047C Use of long pentraxin PTX3 for treatment of diseases caused by altered activation of growth factor FGF-2
03/14/2007CN1304046C Liver cancer relative gene DLK1 and its use
03/14/2007CN1304045C Arthralgia removing pills and their preparation
03/14/2007CN1304043C Longhedan pills and their preparation
03/14/2007CN1304011C Method for the protection of endothelial and epithclial cells during chemotherapy
03/14/2007CN1304009C Nutritional preparation comprising ribose and folic acid and medical use thereof
03/14/2007CN1304008C Medical compsns.
03/14/2007CN1304007C Application of acetyl boswellic acid in preparing antitumor agent
03/14/2007CN1304005C Combinations of receptor tyrosine kinase inhibitor with a1-acidic glycoprotein binding organic compound
03/14/2007CN1304003C Colon positioning and adhering preparation and its preparing process
03/14/2007CN1304000C Use of valsartan in preparing drug for treating lung cancer
03/14/2007CN1303999C Injectable galenic formulation for use in diagnosis or photodynamic therapy and method for preparing same
03/14/2007CN1303997C Method for preparing artemisine and its liposoluble derivatives emulsion
03/14/2007CN1303994C Taxol vesicle injection and its prepn
03/14/2007CN1303993C Soft capsule preparation
03/13/2007US7189856 Central nervous system disorders; vision defects; antiproliferative agents
03/13/2007US7189854 Reacting 4-(2-hydroxyethyl)piperazine and 2-((2-methyl,6-chloro-pyrimidin-4-yl)-amino),5-(2-chloro,6-methyl-phenyl)thiazole to obtain 2-((2-hydroxyethyl)piperazin-4-yl)-(2-methylpyrimidin-6,4-ylene)amino-),5-(2-chloro,6-methyl-phenyl)thiazole; antiarthritic,-tumor, -carcinogentic agents; immunology
03/13/2007US7189837 Cell surface molecule-induced macrophage activation
03/13/2007US7189827 Fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides; recombinant proteins
03/13/2007US7189825 Monoclonal antibody for use in diagnosis, prevention and treatment of cell proliferative disorders; antitumor agents; immunotherapy
03/13/2007US7189820 Antibody for use in the treatment, prevention and diagnosis of cancer, autoimmune, arthritic and graft vs. host diseases
03/13/2007US7189816 Antibody having a binding structure comprising specified complementarity determining region (CDR) sequences for a target tumor antigen on human gastrointestinal epithelial tumour cells; colon cancer diagnosis or immunotherapy
03/13/2007US7189808 Use of carboxy-terminal fragment of Ki-67 protein or of an active part, fragment or homologue thereof as compound that can be used for intracellular transfer and for introduction into and release by cells; antiinflammatory, anticancer agents
03/13/2007US7189801 Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
03/13/2007US7189758 2-Benzyl-2-hydroxy-4-methyl-4-phenylpentanoic acid (1-oxo-1,3-dihydroisobenzofuran-5-yl)amide for example; treating type II diabetes, obesity, hypertension, arteriosclerosis, or glaucoma
03/13/2007US7189756 Pyrrolidine derivatives
03/13/2007US7189745 For use in therapy of diseases, in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred, cytokine antagonist, antiarthritic agent, for therapy of diabetic retinopathy
03/13/2007US7189744 Crystals of benzimidazole compounds
03/13/2007US7189738 Substituted isoindoles and their use thereof
03/13/2007US7189735 Use of CCI-779 as an antineoplastic agent
03/13/2007US7189734 Anilinoquinazaolines as protein tyrosine kianse inhibitors
03/13/2007US7189729 Methods and compositions as protein kinase inhibitors
03/13/2007US7189723 Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
03/13/2007US7189721 Bicyclic protein kinase inhibitors
03/13/2007US7189710 C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
1 ... 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 ... 2211